Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

RedHill Biopharma (RDHL) Cost of Revenue (2016 - 2023)

Historic Cost of Revenue for RedHill Biopharma (RDHL) over the last 8 years, with Q2 2023 value amounting to $806000.0.

  • RedHill Biopharma's Cost of Revenue fell 9103.95% to $806000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $20.5 million, marking a year-over-year decrease of 5332.6%. This contributed to the annual value of $3192.0 billion for FY2024, which is 9228090607.11% up from last year.
  • According to the latest figures from Q2 2023, RedHill Biopharma's Cost of Revenue is $806000.0, which was down 9103.95% from $1.6 million recorded in Q1 2023.
  • RedHill Biopharma's Cost of Revenue's 5-year high stood at $19.3 million during Q4 2021, with a 5-year trough of $417000.0 in Q1 2019.
  • Moreover, its 5-year median value for Cost of Revenue was $8.8 million (2022), whereas its average is $6.9 million.
  • In the last 5 years, RedHill Biopharma's Cost of Revenue soared by 323835.29% in 2020 and then tumbled by 9103.95% in 2023.
  • Quarter analysis of 5 years shows RedHill Biopharma's Cost of Revenue stood at $788000.0 in 2019, then skyrocketed by 1251.78% to $10.7 million in 2020, then soared by 81.51% to $19.3 million in 2021, then crashed by 55.53% to $8.6 million in 2022, then crashed by 90.63% to $806000.0 in 2023.
  • Its Cost of Revenue stands at $806000.0 for Q2 2023, versus $1.6 million for Q1 2023 and $8.6 million for Q4 2022.